Using technological innovation to drive the awakening of beauty, GLYKEN bird's nest peptide leads the new trend in the bird's nest industry

On March 28, 2021, Singapore's GLYKEN Group, the world's leading technology bird's nest manufacturer, held a brand launch conference at 798 Art Factory in Beijing. Its GLYKEN technology bird's nest peptide products were officially launched in China.

Unlike any bird's nest products on the market in the past, GLYKEN uses technological innovation to drive the awakening of beauty and further expands the imagination of bird's nest health care. It has a new definition in terms of nutritional upgrades and eating convenience, and it lives up to its expectations. The name of the new category "Technology Bird's Nest". It is reported that GLYKEN bird's nest peptide series products have been recognized by the China Weightlifting Association and have become the official partner and recommended bird's nest products of the Chinese National Weightlifting Team. Some people in the industry have a premonition that the bird's nest market, which has been pushed up by 100 billion yuan amidst constant doubts, has entered an "incredible" big player. Will it become a "spoiler" or a "subversive" in the bird's nest industry in the future? , people will wait and see.

Singapore GLYKEN’s bird’s nest whole industry chain group with strong scientific research genes

According to official information, GLYKEN Group was established in Singapore in 2010 and has continued to invest in the entire bird's nest industry chain for ten years. It not only owns the world's unique bird's nest industrial park with independent property rights in the Johor Strait, but is also committed to bird's nest biological extraction. Scientific and technological innovation, it is the world's leading institution for bird's nest bioextraction and application research, and has established the only bird's nest extraction and application research center in the industry. The relevant scientific research results have been widely recognized in the European and American biotechnology fields, and it has a number of fourth-generation Bird's nest peptide products and multiple highly valued intellectual copyrights.

GLYKEN’s scientific research genes have been planted since its establishment. Mr. Shak Pui Shong, founder of GLYKEN Group, discovered that Malaysia and Indonesia, as the world's largest producers of bird's nests, have suffered from the negative impact of poisonous bird's nests and fake bird's nests. At that time, the bird's nest industry in Malaysia was still a typical traditional industry with high labor costs, with mostly primary products and low added value. Nutritional research on bird's nests had been blank for a long time, making bird's nests controversial. Mr. Shak Pui Shong believes that only by embracing modern life science and allowing traditional bird's nest culture to break the shackles of "Oriental mysticism" can we follow the development of the times, break through cultural differences, be accepted by people all over the world, and benefit all mankind.

In 2011, GLYKEN cooperated with Universiti Kebangsaan Malaysia to establish the GLYKEN Malaysian Bird’s Nest Biological Laboratory to conduct comprehensive research on the nutrition of bird’s nest extracts. After unremitting scientific research and experimental demonstration, GLYKEN has developed a safe and effective bird's nest extraction technology to extract the proteins and sialic acid contained in the bird's nest into "active glycoprotein peptides". This "glycoprotein peptide" derived from bird's nest has a very significant health care effect on the human body. Glycoprotein is a bridge for human cell signal exchange and transmission. It plays a major role in promoting the replication of human stem cells, repairing damaged cells, and promoting the repair of degenerative knee cartilage tissue. These research results were published in the American Biomedical Center in 2013 and were the first scientific research results in history to scientifically demonstrate the clinical efficacy of edible bird's nest.

The research results of GLYKEN Laboratory are supported by the governments of Singapore and Malaysia. GLYKEN has successively launched scientific research cooperation with three well-known universities including Universiti Teknologi Malaysia (UTM), Universiti Kebangsaan Malaysia (UKM), and the National University of Singapore (NUS) to conduct comprehensive development of bird's nest nutrition. Relying on the scientific research and technological advantages of the three universities, GLYKEN's bird's nest extraction technology has been transformed and applied, and technology bird's nest has successfully achieved stable mass production.

Twenty million self-built Chinese production lines and the world’s advanced bird’s nest extraction technology production line were settled in the Guangxi Free Trade Zone

As early as January 2021, the Guangxi Free Trade Zone issued an official announcement, “Guangxi Free Trade Zone Glyken Bio Products (GuangXi) Co; Ltd has officially passed the review and acceptance by China’s food safety regulatory authorities and obtained the qualification to produce “technological bird’s nest peptides” in China. This marks the official completion and commissioning of the bird's nest production line with the world's leading GLYKEN patented technology in China.

Guangxi Yanshou Biotechnology is a wholly-owned subsidiary invested by Singapore's GLYKEN Group. In April 2020, GLYKEN Group entered Greater China and introduced a complete set of mature foreign patented bird's nest peptide extraction technologies and production systems into China to ensure the consistency of the quality of GLYKEN Technology bird's nest peptides supplied to the world. After three months of investigation, an investment agreement was signed with the China (Guangxi) Pilot Free Trade Zone Qinzhou Port Area Management Committee in August 2020, and the company chose to land in the China-Malaysia Qinzhou Industrial Park, a cooperation park between China and Malaysia.

Leaders of the Guangxi Free Trade Zone who attended the press conference said: "The China-Malaysia Qinzhou Industrial Park is a dual-park transnational cooperation project between the two countries established by the ASEAN trading partners the Chinese government and the Malaysian government. Bird's nest processing The trade base is an important industrial project for the China-Malaysia Qinzhou Industrial Park to promote international production capacity cooperation and the exploration and practice of the "One Belt, One Road" initiative. GLYKEN Group has the world's leading bird's nest deep processing and extraction technology and is the only cutting-edge bird's nest manufacturer in the bird's nest industry. Biotechnology enterprise. GLYKEN Group’s establishment in the Guangxi Free Trade Zone is a major achievement of my country’s Belt and Road economic and trade exchanges, and has effectively promoted international production capacity cooperation between China and Singapore in the field of health. At the same time, for the Guangxi Free Trade Zone, GLYKEN has improved the biotechnology strength of the bird's nest processing and trade base, which is of great significance to Guangxi's layout of the scientific and healthy food industry."

Scientific and technological bird's nest brings a trendy and healthy lifestyle and leads a new track for healthy food.

According to Ms. Huang Caiwei, President of GLYKEN Greater China: "GLYKEN uses bird's nest as raw material, scientifically combines the sialic acid and protein of bird's nest through scientific and technological means, and extracts it into an easy-to-use product. The "small molecule glycoprotein peptides" that are absorbed and utilized by the human body have greatly enhanced the nutritional value of bird's nests. They have also empowered traditional industries through technological innovation and improved industrial efficiency, marking the official launch of the GLYKEN brand. GLYKEN will bring Chinese consumers technological bird's nest products that are more nutritious, more convenient to enjoy, more cost-effective, and have a wider selection. It can be said that GLYKEN bird's nest peptides have redefined bird's nests, creatively integrating traditional Chinese nourishing culture with modernity. The combination of biotechnology will bring revolutionary new breakthroughs to the global bird's nest industry, and will allow small bird's nests to bring great health to mankind."

Today, when young people in China pay attention to health, Chinese people are more interested in high-quality products. The demand is obvious. At the same time, affected by consumption upgrades and the COVID-19 epidemic, the iteration and innovation upgrading of the health food industry are accelerating. The nourishing and health care industry represented by bird's nest has also ushered in the spring of development, with various brands developing rapidly. On the road to chasing this new billion-dollar market, GLYKEN has entered the market with unique patented technologies and products, which may bring a new pattern to the bird's nest industry. We will wait and see.